Kornimate/medical-research-clean huggingface dataset:
cryotherapy in combination with red light pdt for actinic keratosis of full face

Conditions: Actinic Keratoses

Summary: 40 patients randomized 1:1 to receive cryotherapy followed by 10% ala gel red light pdt vs. to 10% ala gel red light pdt followed by cryotherapy.


Eligibility criteria:
inclusion criteria: 1. male or female adult ≥ 18 years of age; 2. 6-12 actinic keratosis grade i, ii, and iii on the full face. 3. willing to avoid excessive sunlight or ultraviolet (uv) light exposure, including the use of tanning beds, to the face or scalp during study participation. 4. females of childbearing potential (fcbp) must have a negative serum pregnancy test at screening and negative urine pregnancy test at baseline. fcbp who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (iud); tubal ligation; or partner's vasectomy; male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. 5. able and willing to give written informed consent prior to performance of any study-related procedures exclusion criteria: 1. presence of other skin conditions that may affect the study participant, investigator's ability to assess treatment, or intolerance to any ingredient in 10% ala gel. 2. treatment with 5-fluorouracil (5-fu), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other topicals and treatments for ak within the treatment area or within 2 cm of the treatment area, within 12 weeks of baseline. 3. use of liquid nitrogen, excision, curettage, dermabrasion, chemical peel or laser resurfacing in the treatment area within 60 days. 4. use of systemic retinoids (eg, isotretinoin, acitretin) within 6 months 5. women of childbearing potential who are pregnant, intend to become pregnant, or are lactating. 6. use of any investigational drug within 4 weeks prior to enrollment or within 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer). 7. any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
a study of the abuse potential of dronabinol in recreational cannabinoid users

Conditions: Drug Abuse, Medication

Summary: the primary objective of this study is to evaluate the abuse potential of dronabinol oral solution in recreational cannabinoid users.

following a four-day period for screening and qualification, there are five treatment visits with a minimum 8-day washout between treatments. each participant will receive all treatments in a 5-way crossover design.

Eligibility criteria:
inclusion criteria: * healthy adult protocol-defined recreational cannabinoid user * meets protocol-specified criteria for qualification and contraception * able to speak, read and understand english well enough to understand the nature of the study, provide written informed consent, and to allow completion of all study assessments * provides written informed consent prior to any protocol-specific procedures, and agrees to abide by all protocol-specified requirements and restrictions exclusion criteria: * dependence on any substance other than nicotine or caffeine beyond protocol-specified limits * signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff, 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding), 3) the analysis of results * unwilling, unable, or unlikely to follow protocol-specified restrictions on food, drink, nicotine or physical activities (such as exercise and driving) * an employee of the sponsor or research site personnel directly affiliated with this study or their immediate biological or adopted family member defined as a spouse, parent, child or sibling
a study of emergency department ai prediction impact

Conditions: Hospital Admission; Length of Stay

Summary: the purpose of this study is to evaluate the impact of an ai admission prediction tool on the number of preventable hospital admissions, emergency department (ed) length of stay, when the predictions are displayed only to a dedicated ed triage team. also, to evaluate user perceptions of the ai tool among the triage team users and medical officer of the day users. additionally, to evaluate any impact of the ai tool on the number of interventions performed by the triage team, and to evaluate the impact of the tool on time-to-admission after an admission order is placed.


Eligibility criteria:
inclusion criteria: * for the survey component, any him clinician that works a shift in the triage area, ed physicians, and the medical officer of the day will be included. * for length of stay data, adult patients registered in the mayo clinic-rochester st. mary's emergency department will be included. exclusion criteria: * for the survey, clinicians not working a triage shift during the study period will be excluded. * for the length of stay analysis, only adult ed patients will be included, who do not triaged to the behavioral health/psychiatry pathway, nor patients who are triaged to the emergency department observation pathway.

Keywords: ai prediction algorithm emergency department
the influence of leg elevation on noradrenaline requirements during cesarean delivery

Conditions: Spinal Hypotension; Hypoperfusion

Summary: spinal anesthesia is a widely chosen technique in obstetric theaters due to several advantages, however sympathetic block results in hypotension that carry several consequences on maternal and fetal health, thus early prediction and management takes high priority. in this regards recent recommendations suggest the use of prophylactic vasopressors like noradrenaline, researchers of this study aimed to explore the impact of leg elevation on prophylactic noradrenaline dose

after spinal anesthesia, patients will be randomly allocated into 2 groups : leg elevation group and control group. noradrenaline will be used as variable infusion starting from 0.05 microgram/kg/min up to 0.14 microgram /kg/minute. noradrenaline infusion will be continued till delivery of the baby

Eligibility criteria:
inclusion criteria: * full term * singleton pregnancy * asa ii exclusion criteria: * decline to participate * baseline sbp \<100 mmhg * failed spinal anesthesia * allergy to local anesthetic * coagulopathy
clinical comparison of two daily wear frequent replacement silicone hydrogel soft contact lenses

Conditions: Refractive Errors; Ametropia

Summary: the primary objective of this study is to evaluate the overall performance of an investigational silicone hydrogel lens when compared to acuvue oasys® with hydraclear® plus (aohp).

part a of this study is a randomized, double masked, crossover study comparing 2 contact lens products. the expected duration of subject participation in part a is approximately 8 weeks with 5 scheduled visits. part b of this study is a non-randomized, single masked, single group study with 1 contact lens product. the expected duration of subject participation in part b is approximately 4 weeks with 3 scheduled visits.

Eligibility criteria:
key inclusion criteria: * sign an approved informed consent form. * wear spherical contact lenses in both eyes for a minimum of 5 days per week and 10 hours per day during the past 3 months. * willing to wear habitual spectacles for vision correction when study lenses are not worn, as needed. * other protocol-defined inclusion criteria may apply. key exclusion criteria: * any eye condition or use of medication that contraindicates contact lens wear, as determined by the investigator. * history of refractive surgery or plan to have refractive surgery during the study. * current or history of dry eye in either eye that, in the opinion of the investigator, would preclude contact lens wear. * routinely sleeps in contact lenses at least 1 night per week. * part a: current wearer of acuvue oasys® with hydraclear® plus. * part b: current wearer of biofinity family of contact lenses (comfilcon a). * other protocol-defined exclusion criteria may apply.

Keywords: contact lenses
use of mesenchymal stem cells in pre-term patients with bronchopulmonary dysplasia.

Conditions: Bronchopulmonary Dysplasia

Summary: bronchopulmonary dysplasia (bpd) is a disease that affects preterm newborn patients, preventing their lungs from developing properly. allogeneic fetal stem mesenchymal cells from umbilical cord could reduce the prevalence of bpd in this patients.

bronchopulmonary dysplasia (bpd) is a disease that affects preterm newborn patients, preventing their lungs from developing properly, and it is a disease that is nowadays increasing due to the improvement in the survival of this patients (affecting 15-50% of them). in the fase i clinical trial, the use of allogeneic fetal stem mesenchymal cells from umbilical cord proved to be safe, with no mortality or adverse events reported. the fase ii clinical trial is based in the hypothesis that the administation of mesenchymal stem cells is not only safe but feasible and can help reducing the chance of a preterm newborn patient developing bpd.

Eligibility criteria:
inclusion criteria: * alive newborns weighing ≤ 1250 grams and ga ≤ 28 weeks, who are on mechanical ventilation with a fio2 ≥0.3 between days 5 and 14 of life, with no immediate extubation foreseeable. exclusion criteria: * presence of another concomitant congenital pathology at the time of inclusion: pulmonary malformations with compromised pulmonary function, active pulmonary haemorrhage, severe pulmonary hypoplasia, renal malformations with systemic compromise, congenital heart disease, polymalformative syndromes, chromosomopathies. * presence of refractory haemodynamic instability of any cause at the time of inclusion. * presence of severe neurological damage at the time of inclusion (hiv grade iii or higher). * patients who have required major surgery in the 72 hours prior to inclusion. * patients who have necrotising enterocolitis (nec) grades ≥ii at the time of inclusion, according to the bell classification. * patients who are children of a mother with hiv

Keywords: bronchopulmonary dysplasia preterm newbnorn mesenchymal stem cells
empiric therapy of patients with persistent fever and agranulocytosis using caspofungin

Conditions: Fungal Infection

Summary: the purpose of this study is evaluating the efficacy and safety of generics caspofungin in the treatment of the patients with neutropenic and fever.another purpose of this study is comparing the pharmacokinetic characteristics of generics caspofungin and original medicine(cancidas®) for providing a basis for clinical rational administration.

caspofungin, a member of the new echinocandin class of compounds，had been proved as effective as and generally better tolerated than liposomal amphotericin b when given as empirical antifungal therapy in patients with persistent fever and neutropenia，and it was approved by fda in 2001.the generics caspofungin of chia tai tianqing pharmaceutical group co. , ltd. (cttq) will be approved by cfda.the purpose of this study is evaluating the efficacy and safety of this generics caspofungin in the empirical antifungal therapy in patients with persistent fever and neutropenia. this is a prospective,multicenter,randomized,controlled,open label study,the designed cases are 60 subjects.this study is divided into two stages,one is pharmacokinetics study stage ,the purpose of this stage is comparing the blood concentration of generics caspofungin and original medicine(cancidas®) ,24 of 60 subjects will participate in this stage,the randomization in a 1:1 ratio will be performed at each group.the other 36 subjects will participate in another stage that is a single study,all subjects will use generics caspofungin.

Eligibility criteria:
inclusion criteria: * age 18-70 years old * the neutrophil counts of the patients with leukemia, lymphoma or other tumors undergoing chemotherapy or receiving hematopoietic stem cell transplantation are below 500 million/l for 96 hours at least,as well as the body temperatures are over 38.0 °c; * it is ineffective using intravenous broad-spectrum antibacterial therapy lasting at least 96h; * estimated survival period \> 3 months; * subjects voluntarily participate in the study and sign informed consent. exclusion criteria: * the subjects did not receive adequate antibacterial therapy; * the subjects were received other antifungal medications within 14 days (except for fluconazole prophylaxis); * it was confirmed or clinically diagnosed as invasive fungal infection; * subjects with liver dysfunction (alt, ast exceeds the upper limit of normal value by 2 times); * subjects with renal insufficiency (cr, bun exceeds the upper limit of the normal value of 1.5 times); * subjects are allergic to the investigational product; * pregnant or lactating women; * simultaneous treatment with cyclosporine, tacrolimus, rifampicin, efavirenz, nevirapine, dexamethasone, phenytoin or carbamazepine; * other circumstances that investigators believe unsuitable for enrollment; （criteria 8 does not apply to phase 2）
nepafenac 0.3% two study

Conditions: Cataract

Summary: the purpose of this study was to assess the safety and efficacy of nepafenac ophthalmic suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.


Eligibility criteria:
inclusion criteria: * planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens; * patients who, in the opinion of the investigator, would have improvement in best-corrected visual acuity after surgery; * able to understand and sign an informed consent; * other protocol-defined inclusion criteria may apply. exclusion criteria: * use of topical ocular, inhaled or systemic nonsteroidal anti-inflammatory drugs within 7 days of surgery, with the exception of the allowed low dose of aspirin (up to 100 mg) prior to surgery and through study exit; * use of topical ocular, inhaled or systemic steroids within 14 days prior to surgery and through study exit; * history of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye; * diabetic retinopathy in the operative eye; * known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (nsaids), or to any component of the test article; * other protocol-defined exclusion criteria may apply.

Keywords: cataract inflammation pain inflammatory cells aqueous flare
increasing serrated polyp detection with a brief awareness training

Conditions: Serrated Polyp; Colorectal Neoplasms

Summary: in this non-randomized controlled trial, a semi-random group of dutch endoscopist receive an oral training about the significance of serrated polyps. the primary aim of this training is to improve the endoscopist's awareness of the significance of serrated polyps, ultimately leading to increased detection. in addition, a random group of endoscopists that will not receive this training will be used as a reference group. data will be collected as part of routine care within the nationwide dutch bowel cancer screening program. the serrated polyp detectionrate of each endoscopist will be extracted from anonymized data that will be prospectively collected as part of routine care within the dutch nationwide bowel cancer screening program. data will be anonymized and provided by rijksinstituut voor volksgezondheid en milieu (rivm) and screenit.


Eligibility criteria:
inclusion criteria: - endoscopists accredited to perform colonoscopies within the dutch nationwide colorectal cancer screening program exclusion criteria: - absent during both training sessions while employed in one of the trained hospitals
the association between hyponatremia and osteoporosis in patients with epilepsy.

Conditions: Hyponatremia; Metabolic Bone Disease

Summary: the study investigates the association between normalization of serum sodium levels and bone markers in patients with epilepsy and chronic hyponatremia. the study is a randomized, single blinded, placebo controlled study where participants will be randomized to either treatment with salt tablets or placebo tablets through 4 months. at the beginning and end of the 4 months bone markers will be measured. the investigators null-hypothesis is that there will be no difference in bone markers before or after the intervention.


Eligibility criteria:
inclusion criteria: * epilepsy requiring treatment for at least 2 years * known hyponatremia (2 subsequent s-sodium values \< 136 mmol/l) * age 18-80 years * danish speaking * signed form of prior consent exclusion criteria: * pregnancy and breastfeeding * known osteoporosis. dxa scan \< -2.5 t-score. z-score is used for patients 50 years or younger. * undergoing treatment for osteoporosis * undergoing treatment with salt tablets * known siadh * severe concomitant disease such as cancer or ischemic heart disease * alcohol, drug or substance abuse
clinical study on the treatment of diabetic kidney disease with shenxiao yuning decoction with syndrome of qi and yin deficiency and blood stasis

Conditions: Diabetic Kidney Disease

Summary: to explore the therapeutic effect of shenxiao yuning decoction on albuminuria and the improvement of traditional chinese medicine syndrome in patients with stage iii diabetic kidney disease with qi and yin deficiency and blood stasis syndrome.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for albuminuria in type 2 diabetic nephropathy, persistent albuminuria, and 2 consecutive urine microalbumin/creatinine (acr) \>30mg/g within 3 months; * the glomerular filtration rate egpr ≥ 60ml/min/1.73m2, and is required to remain stable during the trial (egfr decreases ≤25% from the beginning of screening to the second week of follow-up); * those who are consistent with the syndrome of diabetes and kidney disease, deficiency of qi and yin and blood stasis; * gender is not limited, age is 18-75 years old, bmi≤45 kg/m2; * glycated hemoglobin (hba1c) 6-11%, fasting blood glucose (fpg) ≤15 mmol/l; * systolic blood pressure/diastolic blood pressure (sbp/dbp) ≤180/100 mmhg (sitting); * those who have complete medical records, voluntarily participate in this clinical study, and sign the informed consent form. exclusion criteria: * pregnant and lactating women; * acute complications of diabetes such as hypoglycemic coma, diabetic ketosis, lactic acidosis, etc. have recently occurred; * those combined with heart failure and myocardial infarction; combined with infections, immune diseases, and malignant tumors; combined with liver diseases (alt, ast or alp levels exceed three times the upper limit of normal); * male serum creatinine (scr) ≥1.50 mg/d1 (114.4 μmol/l), or female serum creatinine ≥1.40 mg/dl (106.8 μmol/l); * those who are combined with other kidney and renovascular diseases, or those who have other causes such as excessive exercise, heart failure, febrile infections, or urinary tract infections that lead to elevated urinary microalbumin; * those who have used nephrotoxic drugs and antioxidants, or used systemic glucocorticoid therapy in the past 2 weeks; * those undergoing dialysis or kidney transplantation; * history of bariatric surgery or other gastrointestinal surgery causing chronic malabsorption within 2 years; * persons with drug contraindications: pregnant or lactating women, allergic constitutions, and those allergic to the drugs used in this study; * those who are unable to cooperate due to severe mental illness or mental disorder; * those who have not signed the informed consent form.

Keywords: shenxiao yuning decoction diabetic kidney disease
an outpatient study of the efficacy of ars-2 in patients with chronic spontaneous urticaria

Conditions: Urticaria Chronic

Summary: this is a phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. subjects enrolled will have csu with a history of moderate to severe acute exacerbations (or flares).


Eligibility criteria:
inclusion criteria: * is a male or female between the ages of 18 and 65 years, inclusive. * has been clinically diagnosed with csu and experiences an acute flare of moderate to severe urticaria symptoms (itch and hive severity uas score ≥ 2) approximately 1-2 times a month or every other month consistently during the past year while on a chronic treatment. * has been on a daily chronic treatment for ≥ 6 weeks. * is willing to use a smartphone study application to record study assessments and aes. * has body weight more than 15 kilogram (kg). * has no medical history of clinically significant hypertension and cardiovascular disease in the last 10 years * if female, is not pregnant or breastfeeding based on a negative urine pregnancy test at baseline. * is able to communicate clearly with the investigator and staff; able to read, complete questionnaires, and perform study procedures on the smartphone study application. * is willing and able to provide written informed consent prior to participating in the study. * controlled hypertension without beta blocker confirmed by the investigator is acceptable. * at screening, has stable vital signs in the following ranges (after 5 minutes of rest): * systolic blood pressure (sbp) ≥90 and ≤140 milliliters of mercury (mmhg) * diastolic blood pressure (dbp) ≥50 and ≤90 mmhg * heart rate (hr) ≥45 and ≤100 beats per minute (bpm) exclusion criteria: * has a history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results. * has any clinically significant medical condition or pe finding as deemed inappropriate by the investigator. * has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal electrocardiogram (ecg) * has had significant traumatic injury or major surgery within 30 days prior to study screening. * known hypersensitivity to any compound in the test product, or any other closely related compound (e.g., dihydropyridine-derived molecules). * has participated in a clinical trial within 30 days prior to the first dose of study drug. * has an immediate family member of the investigator, or an employee of the study center, with direct involvement in the proposed study, or other studies under the direction of the investigator or study center or is in a dependent relationship with a study center employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under duress.